SELLAS Life Sciences (SLS) Research & Development (2010 - 2026)
SELLAS Life Sciences (SLS) reported Research & Development of $5.1 million for Q1 2026, up 60.03% year-over-year from $3.2 million in Q1 2025, and up 8.44% on a QoQ basis from $4.7 million in Q4 2025.
SELLAS Life Sciences (SLS) has 17 years of Research & Development data on file, last reported at $5.1 million in Q1 2026.
- Quarterly Research & Development rose 60.03% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $17.9 million (up 4.4% YoY) and the FY2025 annual result came in at $16.0 million, down 16.1% from the prior year.
- Research & Development grew to $5.1 million in Q1 2026 per SLS's latest filing, from $4.7 million in the prior quarter.
- Across five years, Research & Development topped out at $7.2 million in Q1 2023 and bottomed at $3.2 million in Q1 2025.
- The 5-year median for Research & Development is $5.1 million (2023), against an average of $5.0 million.
- The widest annual swing landed in 2022, when Research & Development soared 72.3%; it then plunged 37.29% in 2025.
- Tracing SLS's Research & Development over 5 years: stood at $5.8 million in 2022, then retreated by 12.81% to $5.1 million in 2023, then slipped by 12.95% to $4.4 million in 2024, then climbed by 6.6% to $4.7 million in 2025, then grew by 8.44% to $5.1 million in 2026.
- Per Business Quant, the three latest SLS Research & Development figures stand at $5.1 million (Q1 2026), $4.7 million (Q4 2025), and $4.2 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | SELLAS Life Sciences | 1.61 Bn | 1.61 Bn | - | 5.13 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5.13 Mn |
| Dec 31, 2025 | 4.73 Mn |
| Sep 30, 2025 | 4.22 Mn |
| Jun 30, 2025 | 3.87 Mn |
| Mar 31, 2025 | 3.21 Mn |
| Dec 31, 2024 | 4.44 Mn |
| Sep 30, 2024 | 4.36 Mn |
| Jun 30, 2024 | 5.19 Mn |
| Mar 31, 2024 | 5.11 Mn |
| Dec 31, 2023 | 5.10 Mn |
| Sep 30, 2023 | 5.81 Mn |
| Jun 30, 2023 | 5.92 Mn |
| Mar 31, 2023 | 7.17 Mn |
| Dec 31, 2022 | 5.85 Mn |
| Sep 30, 2022 | 4.28 Mn |
| Jun 30, 2022 | 5.53 Mn |
| Mar 31, 2022 | 4.61 Mn |
| Dec 31, 2021 | 3.39 Mn |
| Sep 30, 2021 | 4.54 Mn |
| Jun 30, 2021 | 3.46 Mn |
| Mar 31, 2021 | 4.28 Mn |
| Dec 31, 2020 | 2.77 Mn |
| Sep 30, 2020 | 2.37 Mn |
| Jun 30, 2020 | 2.28 Mn |
| Mar 31, 2020 | 1.86 Mn |
| Dec 31, 2019 | 2.25 Mn |
| Sep 30, 2019 | 1.80 Mn |
| Jun 30, 2019 | 1.38 Mn |
| Mar 31, 2019 | 1.86 Mn |
| Dec 31, 2018 | 3.65 Mn |
| Sep 30, 2018 | 1.72 Mn |
| Jun 30, 2018 | 1.59 Mn |
| Mar 31, 2018 | 1.80 Mn |
| Dec 31, 2017 | 988,000.00 |
| Sep 30, 2017 | 1.07 Mn |
| Jun 30, 2017 | 1.83 Mn |
| Mar 31, 2017 | 2.18 Mn |
| Dec 31, 2016 | -3.85 Mn |
| Sep 30, 2016 | 3.62 Mn |
| Jun 30, 2016 | 6.18 Mn |
| Mar 31, 2016 | 5.44 Mn |
| Dec 31, 2015 | 4.85 Mn |
| Sep 30, 2015 | 5.74 Mn |
| Jun 30, 2015 | 7.20 Mn |
| Mar 31, 2015 | 5.83 Mn |
| Dec 31, 2014 | 6.21 Mn |
| Sep 30, 2014 | 7.03 Mn |
| Jun 30, 2014 | 8.07 Mn |
| Mar 31, 2014 | 6.77 Mn |
| Dec 31, 2013 | 6.43 Mn |
| Sep 30, 2013 | 3.63 Mn |
| Jun 30, 2013 | 5.28 Mn |
| Mar 31, 2013 | 5.08 Mn |
| Dec 31, 2012 | 4.45 Mn |
| Sep 30, 2012 | 4.17 Mn |
| Jun 30, 2012 | 3.67 Mn |
| Mar 31, 2012 | 2.66 Mn |
| Dec 31, 2011 | 2.05 Mn |
| Sep 30, 2011 | 1.37 Mn |
| Jun 30, 2011 | 329,000.00 |
| Mar 31, 2011 | 2.16 Mn |
| Dec 31, 2010 | 1.75 Mn |
| Sep 30, 2010 | 1.94 Mn |
| Jun 30, 2010 | 2.26 Mn |